Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study-Reference-Cited by-同舟云学术

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

Published:2016-12-30 Issue:4 Volume:88 Page:285-294
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:J Neurol Neurosurg Psychiatry

Author:

Comi Giancarlo,De Stefano Nicola,Freedman Mark S,Barkhof Frederik,Uitdehaag Bernard M J,de Vos Marlieke,Marhardt Kurt,Chen Liang,Issard Delphine,Kappos Ludwig

Publisher

BMJ

Subject

Psychiatry and Mental health,Clinical Neurology,Surgery

Reference37 articles.

1. Multiple sclerosis;Noseworthy;N Engl J Med,2000

2. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial;Comi;Lancet Neurol,2012

3. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study;Comi;Lancet,2001

4. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes;Kappos;Neurology,2006

5. New diagnostic criteria for multiple sclerosis: guidelines for research protocols;Poser;Ann Neurol,1983

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of a semi-automated method to quantify lesion volume changes in multiple sclerosis on 2D proton-density-weighted scans based on image subtraction;Neuroimage: Reports;2024-03

2. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

3. Disease-modifying therapies;Clinical Aspects of Multiple Sclerosis Essentials and Current Updates;2024

4. Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes;Multiple Sclerosis Journal;2023-11-29

5. Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study;Frontiers in Neurology;2023-11-28